NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense’s Phase IIa study with PrimeC.


Join Our Newsletter

Skip to content